Comparison between cytomegalovirus and HIV viral load among HIV patient who underwent antiretroviral therapy
Main Article Content
Keywords
Cytomegalovirus, Cytomegalovirus viral load, HIV, HIV viral load, Antiretroviral therapy, Q-PCR
Abstract
Introduction: Cytomegalovirus (CMV) is one of the most prevalent viral infections in humans. The prevalence is approximately 20 percent among children and nearly 100 percent among adults. Among immunocompetent individuals, CMV infection remains predominantly asymptomatic. However, in immunocompromised patients such as people with HIV (PWH), it can cause end-organ diseases that may be life-threatening. With the increasing administration of antiretroviral therapy (ART), HIV infection can be controlled, and complications from CMV infection have been decreasing. One critical method for monitoring CMV infection is identifying CMV viremia. This study aims to investigate whether CMV viremia persists in PWH undergoing ART and to explore its relationship with HIV viral load. The research seeks to provide insights to guide clinical management of CMV reactivation in this patient population
Methods: This cross-sectional study analysed archived plasma samples to detect and compare CMV viral load and HIV viral load among PWH undergoing ART. The samples were archived biological materials collected for HIV viral load detection. All samples were previously tested by PCR to detect CMV. Data were analysed using the Mann-Whitney test and Spearman correlation test.
Result: Among 67 total samples, seven were identified as CMV positive, displaying various viral load concentrations. Analysis using the Mann-Whitney test demonstrated a statistically significant difference between variables, while the Spearman correlation test showed no correlation between them. This indicated that CMV viremia may not be directly influenced by HIV infection.
Conclusion: Despite the significant difference between variables, the CMV viral load among PWH undergoing ART was not correlated with HIV viral load status. These findings suggest that CMV monitoring should be considered independently of HIV viral load status. However, the limited sample size suggests caution in generalizing these findings.
References
2. Burrell CJ, Howard CR, Murphy FA. Fenner and White’s Medical Virology. Fifth Edition. San Diego: Academic Press; 2017.
3. Wang YQ, Zhao XY. Human Cytomegalovirus Primary Infection and Reactivation: Insights From Virion-Carried Molecules. Front Microbiol. 2020;11(July).
4. Gianella S, Letendre S. Cytomegalovirus and HIV: A Dangerous Pas de Deux. Journal of Infectious Diseases. 2016;214(Suppl 2):S67–74.
5. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1(October).
6. Rinaldo CR. Cytomegalovirus: 40 years and still the major viral cofactor in HIV infection. Aids. 2022;36(9):1311–3.
7. Kiros M, Geteneh A, Andualem H, Alemu D, Tesfaye A, Tefera DA, et al. Human cytomegalovirus infection among treatment-naive HIV-1 infected patients in Ethiopia. PLoS One. 2021;16(2 February):1–8. Available from: http://dx.doi.org/10.1371/journal.pone.0247264
8. Gianella S, Anderson CM, Vargas M V., Richman DD, Little SJ, Morris SR, et al. Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA. Journal of Infectious Diseases. 2013;207(6):898–902.
9. Hatano H. Immune activation and HIV persistence: Considerations for novel therapeutic interventions. Curr Opin HIV AIDS. 2013;8(3):211–6.
10. Mana H Al, Yassine HM, Younes NN, Al-Mohannadi A, Al-Sadeq DW, Alhababi D, et al. The current status of cytomegalovirus (CMV) prevalence in the MENA region: A systematic review. Pathogens. 2019;8(4).
11. Levi LI, Sharma S, Schleiss MR, Furrer H, Nixon DE, Blackstad M, et al. Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. Aids. 2022;36(9):1265–72.
12. Fielding K, Koba A, Grant AD, Charalambous S, Day J, Spak C, et al. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among hiv-infected gold miners in South Africa. PLoS One. 2011;6(10).
13. Mizushima D, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, et al. Diagnostic utility of quantitative plasma cytomegalovirus DNA PCR for cytomegalovirus end-organ diseases in patients with HIV-1 infection. J Acquir Immune Defic Syndr (1988). 2015;68(2):140–6.
14. Rzepka M, Depka D, Gospodarek-Komkowska E, Bogiel T. Whole Blood versus Plasma Samples—How Does the Type of Specimen Collected for Testing Affect the Monitoring of Cytomegalovirus Viremia? Pathogens. 2022;11(11).